Latest News

29 April 2021

International Task Force Determines Current Parkinson’s Disease Subtyping May Not Fit All Patients

Amsterdam, NL – The clinical presentation and underlying biology of Parkinson’s disease (PD) varies significantly, but attempts to cluster cases into a limited number of subtypes have questionable applicability and relevance, reports the international

3 February 2021

COVID-19 Vaccination for Patients with Parkinson’s Disease Recommended

Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in JPD, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication.

25 September 2020

JPD and MJFF Accelerating the Publication of Parkinson's Disease Publication Data

Call for Submissions: To address the bias toward the publication of novel positive results, The Michael J. Fox Foundation for Parkinson’s Research and JPD invite researchers to “open their notebooks” and submit unpublished results from experiments that attempted to replicate previously published findings from other laboratories.

22 September 2020

Neurological Consequences of COVID-19: The “Silent Wave”

Is the world prepared a wave of neurological consequences that may be on its way as a result of COVID-19? This question is at the forefront of research underway at the Florey Institute of Neuroscience and Mental Health. A team of neuroscientists and clinicians are examining the potential link between COVID-19 and increased risk of Parkinson’s disease, and measures to get ahead of the curve.

3 August 2020

The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease

Amsterdam, NL – A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated. Investigators report that the outlook for patients is encouraging, given the wide range of therapeutics being clinically tested. They emphasize the importance of engaging the Parkinson's community in the research. Their analysis and results are published in the >Journal of Parkinson's Disease.

Pages

Subscribe to Latest News